Main Story
-
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants – – Majority of verekitug-treated participants experienced clinically meaningful improvements across key secondary endpoints, including 72% in nasal congestion and 83% in CRSwNP total symptom score – WALTHAM, Mass., June 14, 2026 (GLOBE…
Automobile
Tech
Entertainment
-
Dance Without Borders: BYU Ballroom Dance Gives Historic Performances in India
New Delhi | Bengaluru, India The BYU Ballroom Dance Company lit up stages in India for the first time, enchanting over 1,000 audience members with show-stopping performances held on 4 and 6 June 2026 in the nation’s capital and a grand finale in Bengaluru on 9 June. Distinguished guests, including government, interfaith, and community leaders,…
Health
-
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants – – Majority of verekitug-treated participants experienced clinically meaningful improvements across key secondary endpoints, including 72% in nasal congestion and 83% in CRSwNP total symptom score – WALTHAM, Mass., June 14, 2026 (GLOBE…
-
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for the combination arm vs 28% for the control arm at week 24. Post-hoc analysis from the phase 3 SENTRY trial suggests SVR35 may predict overall survival (OS); new data from the…
-
QNET DENIES ANY ASSOCIATION WITH IGNITE
HYDERABAD, India, June 13, 2026 /PRNewswire/ — QNET has taken note of recent media reports published in Telangana concerning the alleged activities of an entity operating under the name IGNITE, as well as references that seek to associate those activities with QNET and its franchisee in India, Vihaan Direct Selling (India) Pvt. Ltd. Given the…
-
Exploratory Efficacy Data Suggests Further Study of Peanut Tolerance with Oral Mucosal Immunotherapy (OMIT)
NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) — Intrommune Therapeutics, Inc., a clinical-stage biotechnology company committed to developing a patient-friendly treatment platform for people with peanut and other food allergies, today announced the presentation of exploratory efficacy data from the Oral Mucosal Escalation Goal Assessment (OMEGA) Phase 1 safety trial at the 2026 Eastern Allergy…
-
UCB Transforms Safety Operations with Veeva Safety Suite in Collaboration with ELIQUENT Life Sciences, Pinnaxis, and Daelight Solutions
WASHINGTON, June 12, 2026 /PRNewswire/ — ELIQUENT Life Sciences (“ELIQUENT”) today announced the June 1 go-live of Veeva Safety Suite at UCB. As one of the first organizations to adopt the complete suite, UCB is unifying its global safety operations in a transformation delivered through a strategic collaboration between Veeva, ELIQUENT, Pinnaxis, and Daelight Solutions.…
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
